Transdermal permeation of novel n-acetyl-glucosamine/NSAIDs mutual prodrugs

Pharmaceutical Development and Technology

Volumn 17, Issue 1, 2012, Pages 48-54

  Israel, Bridg'Ette ^a,b   Garner, Solomon T ^a,b   Thakare, Mohan ^a   Elder, Deborah ^a   Abney, Trinia ^a   Azadi, Parastoo ^a   Beach, J Warren ^a   Price, James C ^a   Ahmed, Hisham ^a   Capomacchia, Anthony C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b ALFRED P SLOAN FOUNDATION   (United States)

Author keywords

Glucosamine; Mutual prodrug; N acetyl Glucosamine; NSAID; Osteoarthritis; Transdermal permeation

Indexed keywords

IBUPROFEN; KETOPROFEN; N ACETYLGLUCOSAMINE; PRODRUG;

ANIMAL TISSUE; ARTICLE; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SNAKE;

ACETYLGLUCOSAMINE; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL MEMBRANE PERMEABILITY; DRUG COMBINATIONS; ETHANOL; HYDROLYSIS; IBUPROFEN; INDICATORS AND REAGENTS; KETOPROFEN; KINETICS; PRODRUGS; SKIN ABSORPTION; SNAKES; SOLUBILITY; SOLVENTS;

EID: 83455181606     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2010.513987     Document Type: Article

References (46)

1. Albert A. Chemical aspects of selective toxicity. Nature 1958;182(4633):421-423.
2. Rao H, Surya Prakash. Capping drugs: Development of prodrugs. Accessed February 2003 from the website: Http://www.ias.ac.in/ resonance/Feb2003/pdf/ Feb2003p19-27.pdf.
3. Capelli L, Chianese V, La Montagna G, Giordano M. Further studies on glucametacin in rheumatoid arthritis and in other chronic types of rheumatism. Curr Med Res Opinion 1981;7(4):227-233. (Pubitemid 11118429)
4. Singh G, Sharma PD. Review article: Mutual prodrugs-A recent trend in prodrug design. Indian J Pharm Sci 1994;56(3):69-79. (Pubitemid 24213983)
5. Ueda I, Tani M. Histamine and its related active substances: Synthesis and pharmacological properties a new chimera drug derived from the combination of anti-inflammatory agent histamine H2 receptor antagonist. Mem Inst Sci Ind Res Osaka Univ 1990;43-54.
6. Imai T, Fukuhara Ueda I, Otagiri M. An evaluation of an antiinflammatory-histamine H2 antagonist drug complex on gastric corrosions in the rat. J Pharmacol Exp Ther 1994;265:Exp. 328-333. (Pubitemid 23320978)
7. Fukuhara A, Imai T, Inoue K, Otagiri M. Effect of oral multipledose administration Fukuhara, Imai, Inoue, of anti-inflammatory flurbiprofen chimera drug on gastric lesion, other toxicities and disposition toxicities. Biol Pharm Bull 1995;18:140-147.
8. Fukuhara A, Imai T, Otagiri M. Stereoselective disposition of flurbiprofen from a Fukuhara, Imai, disposition from mutual prodrug with a histamine H2-antagonist to reduce gastrointestinal lesions in the rat. Chirality 1996;8:494-502. (Pubitemid 27009143)
9. Otagiri M, Imai T, Fukuhara A. Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimer drug. J Con Release 1999;62:223-229. (Pubitemid 29486501)
10. Capomacchia AC, and, US Provisional patent application No. 60/560,128, filed 7 April 2004. Glucosamine and glucosamine/ anti-inflammatory mutual prodrugs, compositions, and methods.
11. Capomacchia AC, Garner ST. US Patent application 235.00560201, filed 7 April 2005. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods.
12. Ghodeswar BC, Pophalikar RN, Bhojani MR, Nagpal D, Dhaneshwar SS. Synthesis and pharmacological evaluation of mutual prodrugs of some nonsteroidal antiflammatory drugs with glucosamine. Indian J Pharm Sci 2004;66:773-777.
13. Bhosale AV, Agrawal GP, Mishra P. Preparation and characterization of mutual prodrugs of ibuprofen. Indian J Pharm Sci 2003;66(2):158-163.
14. Garner ST, et al. Transdermal permeability of NAG. Pharmaceut Dev Tech 2007;12:169-174.
15. Yuan X, Capomacchia AC. The binary eutectic of NSAIDs and two-phase liquid system for enhanced membrane permeation. Pharmaceut Develop Technol 2005;1:1-10. (Pubitemid 40315524)
16. Qandil et al. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery. Drug Dev Ind Pharm 2008;34:1054-1063.
17. Babazadeh M. Design, synthesis and in vitro evaluation of vinyl ether type polymeric prodrugs of ibuprofen, ketoprofen and naproxen. Int J Pharm 2008;356:167-173.
18. Silva DJ, et al. J Org Chem 1999;64:5926-5929 (Supplemental material).
19. Itoh T, Xia J, Magavi R, Nishihata T, Rytting JH. Use of shed snake skin as a model membrane for in vitro percutaneous penetration studies: Comparison with human skin. Pharm Res 1990;7:1042-1047. (Pubitemid 20366732)
20. Higuchi T, Konishi R. In vitro testing and transdermal delivery. Proceedings of the 2nd Transdermal Therapeutic Symposium. Therapeutic Res 1987;6:280-288.
21. Ngawhirunpat T, Panomsuk S, Opanasopit P, Rojanarata T, Hatanaka T. Comparison of the percutaneous absorption of hydrophilic and lipophilic compounds in shed snake skin and human skin. Pharmazie 2006;61(4):331-335.
22. Ngawhirunpat T, Opansopit P, Rojanarata T, Panomsuk S. Evaluation of simultaneous permeation and metabolism of methyl nicotinate in human, snake, and shed snake skin. Pharmaceut Develop Technol 2008; 13:75-83. (Pubitemid 351304470)
23. Franz TJ, Lehman PA, Kagy MK. Dimethyl sulfoxide. In: Smith EW, Maibach HI, editors. Percutaneous enhancers. Boca Raton, FL: CRC Press; 1995:112-127.
24. Swart H, et al. Synthesis and transdermal penetration of NSAID glycoside esters. Int J Pharm 2005;301:71-79. (Pubitemid 41206592)
25. Bonina FP, Puglia C, Barbuzzi T, Caprariis PD, Rimoli MG. In vitro and in vivo evaluation of polyoxyethenene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci 2001;14:123-134.
26. Doh H-J, Cho WJ, Yong CS, Choi HG, Kim JS, Lee CH. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci 2003;92:1008-1017. (Pubitemid 36523446)
27. Kim B-Y, et al. Ketorolac amide prodrugs for transdermal delivery: Stability and in vivo transdermal stability rat skin permeation studies. Int J Pharm 2004;293:193-202. (Pubitemid 40381092)
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23(1-3):3-25. (Pubitemid 27046991)
29. The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co, 1996; pp 758, 839, 905.
30. D'Souza AJM, Topp EM. Release from polymeric prodrugs: Linkages and their degradation. J Pharm Sci 2004;93(8):1962-1979. (Pubitemid 39045479)
31. McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 1996;45:1003-1009. (Pubitemid 26260150)
32. Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED. Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: The involvement of protein kinases A and C. Diabetes 2001;50:2355-2362. (Pubitemid 33641923)
33. Miwa I, Mita Y, Murata T, Okuda J, Sugiura M, Hamada Y, Chiba T. Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Enzyme Protein 1994;48:135-142.
34. Van Schaftigen E. Glucosamine-sensitive and-insensitive detritiation of [2-3H] glucose in isolated rat hepatocytes: A study of the contributions of glucokinase and glucose-6-phosphatase. Biochem J 1995;308:23-29.
35. Virkamaki A, Yki-Jarvinen H. Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Diabetes 1999;48:1101-1107. (Pubitemid 29226358)
36. Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, Terlain B, Bordji K. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level and by inhibiting the NF-B pathway. FEBS Lett 2002;510:166-170. (Pubitemid 34093818)
37. Poustie MW, Carran J, McEleney K, Dixon SJ, Anastassiades TP, Bernier SMJ. N-butyryl glucosamine increases matrix gene expression by chondrocytes. Pharmacol Exp Ther 2004;311(2):610-616. (Pubitemid 39391546)
38. Anastassiades TP. Treatment of arthritis and compositions therefore. 2001. United States Patent Application No. 20020045597.
39. Anastassiades TP. Methods and compositions using N-acyl 2-glucosamine derivatives for the treatment of arthritis. 2002. PCT Int. Appl. WO 2002017890 A2 20020307 CAN 136:210563 AN 2002:171660.
40. Anastassiades TP. Amelioration of decreased weight and growth by N-acylated glucosamines. 2003. United States Patent Application No. 20040152665.
41. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittel-Forschung 1986;36(4):729-735. (Pubitemid 16166103)
42. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittel-Forschung 1993;43(10):1109-1113. (Pubitemid 23311890)
43. Setnikar I, Rovati LC. Absorption, distribution, metabolism,and excretion of glucosamine sulfate. A review. Arzneimittel-Forschung 2001;51(9):699-725.
44. Setnikar et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharmaceut Drug Disposit 2004;25(3):109-116.
45. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of pharmacokinetics glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharmaceut Drug Disposit 2004;25(3):109-116. (Pubitemid 39089553)
46. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharmaceut Sci 2000;5(2):181-184.